Skip to main content
OSE Immunotherapeutics logo

OSE Immunotherapeutics — Investor Relations & Filings

Ticker · OSE ISIN · FR0012127173 LEI · 969500HIUWVGY6NZSM05 PA Manufacturing
Open in API
Filings indexed 815 across all filing types
Latest filing 2026-05-22 Regulatory Filings
Country FR France
Listing PA OSE

About OSE Immunotherapeutics

https://www.ose-immuno.com/en/home/

OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering first-in-class therapies that control the immune system. The company's pipeline is concentrated in two key areas: immuno-oncology (IO) and immuno-inflammation (I&I). In immuno-oncology, its research aims to help the immune system recognize and target tumors. In immuno-inflammation, it develops treatments for autoimmune diseases and chronic inflammation by regulating immune responses. OSE Immunotherapeutics utilizes proprietary drug discovery platforms to generate novel product candidates, including monoclonal antibodies and RNA therapeutics, and collaborates with pharmaceutical partners to advance its assets through clinical development.

Recent filings

Filing Released Lang Actions
OSE Immunotherapeutics annonce les résultats de Topline positifs de l'étude de Phase 2 TEDOVA de Tedopi® dans le cancer de l’ovaire en rechute
Regulatory Filings Classification · 80% confidence The document is a corporate press release announcing topline Phase 2 clinical study results for Tedopi®, with details on study design, efficacy endpoints, and upcoming presentation/webcast. It contains no financial statements or regulatory filings, no request for shareholder votes, no management changes, no dividend, no M&A. It is not an earnings release (no revenue or profit figures), nor an investor presentation/slides, nor a quarterly/interim report. Therefore it falls into the miscellaneous Regulatory Filings category (RNS) as a general corporate announcement.
2026-05-22 French
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
Regulatory Filings Classification · 85% confidence The document is a press release announcing clinical trial topline results and upcoming presentation/webcast dates. It contains no financial statements, no executive certifications, no shareholder votes, no merger or financing details, and no substantive reporting content. It is a general corporate/regulatory announcement about clinical data, fitting the fallback category for miscellaneous regulatory communications.
2026-05-22 English
Informations relatives au nombre total de droits de vote et d’actions composant le capital
Declaration of Voting Results & Voting Rights Announcements
2026-05-06 French
OSE Immunotherapeutics publie ses résultats financiers consolidés non audités pour l’exercice 2025 et sa situation de trésorerie du 1er trimestre 2026
Regulatory Filings
2026-04-30 French
OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position
Regulatory Filings
2026-04-30 English
OSE Immunotherapeutics se félicite de l'octroi de la désignation de médicament orphelin par la FDA du pegrizeprument (VEL-101) pour la prévention du rejet d’organe dans la transplantation cardiaque
Regulatory Filings Classification · 55% confidence The document is a corporate press release announcing that OSE Immunotherapeutics’ partner Veloxis Pharmaceuticals received orphan drug designation from the U.S. FDA for pegrizeprument (VEL-101). It does not present financial results, regulatory filings like an annual or quarterly report, nor management changes, share transactions, dividends, or proxy materials. It is a general corporate announcement of a regulatory milestone. There is no specific filing category for orphan drug designations, so the appropriate category is the fallback 'Regulatory Filings' (RNS).
2026-04-27 French

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.